Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 9 of 9 entries
View as:

A Randomized, Dose-ranging Study of Alferon LDO in Asymptomatic HIV+ Subjects

Phase: N/A Priority: Normal
NCT ID: NCT00215852 Org: User:
Start: 07/31/05 End: 04/30/09 Due: 04/30/10

The Study of the Safety and Efficacy of Ampligen in Chronic Fatigue Syndrome

Phase: N/A Priority: Normal
NCT ID: NCT00215800 Org: User:
Start: 12/31/98 End: 02/29/04 Due: 02/28/05

Study of Alferon® LDO (Low Dose Oral) in Normal Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT00215826 Org: User:
Start: 11/30/04 End: 04/30/06 Due: 04/30/07

Safety Study of FluMist With and Without Ampligen

Phase: N/A Priority: Normal
NCT ID: NCT01591473 Org: User:
Start: 04/30/12 End: 08/31/15 Due: 08/31/16

Ampligen in Chronic Fatigue Syndrome

Phase: N/A Priority: Normal
NCT ID: NCT00215813 Org: User:
Start: - End: - Due: -

The Role of Ampligen in Strategic Therapeutic Intervention (STI) of HAART

Phase: N/A Priority: Normal
NCT ID: NCT00035893 Org: User:
Start: 05/31/01 End: 08/31/06 Due: 08/31/07

Safety and Efficacy of Ampligen in the Treatment of HIV Patients Failing HAART

Phase: N/A Priority: Normal
NCT ID: NCT00035581 Org: User:
Start: 05/31/01 End: 09/30/05 Due: 09/30/06

Ampligen Combined With SOC Versus SOC Alone Following First-Line Therapy in Subjects With LAPC

Phase: N/A Priority: Normal
NCT ID: NCT05494697 Org: User:
Start: 07/31/25 End: 10/31/28 Due: 10/31/29

Study to Evaluate the Efficacy and Safety of Ampligen in Patients With Post-COVID Conditions

Phase: N/A Priority: Normal
NCT ID: NCT05592418 Org: User:
Start: 06/30/23 End: 11/30/23 Due: 11/30/24